Report of the fourth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses', World Health Organization and Wellcome Trust, London, United Kingdom, 9-10 November 2009. (Q39882249)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Report of the fourth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses', World Health Organization and Wellcome Trust, London, United Kingdom, 9-10 November 2009.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Report of the fourth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses', World Health Organization and Wellcome Trust, London, United Kingdom, 9-10 November 2009. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

World Health Organization

0 references

3

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Frederick G Hayden

2

object named as

Frederick Hayden

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

author name string

Iain Stephenson

1

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Wendy Howard

4

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Yuri Pervikov

5

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Laszlo Palkonyay

6

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Marie-Paule Kieny

7

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

language of work or name

0 references

publication date

14 April 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

3875-3882

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Report of the third meeting on “Influenza vaccines that induce broad spectrum and long-lasting immune responses”, World Health Organization, Geneva, Switzerland, 3–4 December 2007

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Report of the second meeting on the development of influenza vaccines that induce broad-spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 6-7 December 2005.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Report of meeting on the development of influenza vaccines with broad spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 26-27 February 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Mapping the antigenic and genetic evolution of influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Comparative efficacy of inactivated and live attenuated influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Influenza virus-specific cytotoxic T cells in man; induction and properties of the cytotoxic cell

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Cytotoxic T-cell immunity to influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

T cell responses are better correlates of vaccine protection in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Safety of MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

The effect of universal influenza immunization on mortality and health care use.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Novel approach to the development of effective H5N1 influenza A virus vaccines: use of M2 cytoplasmic tail mutants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Attenuated influenza A viruses with modified cleavage sites in hemagglutinin as live vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Using plant cells as influenza vaccine substrates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

An in-built proteinase inhibitor system for the protection of recombinant proteins recovered from transgenic plants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patch

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.074

7 January 2021

Identifiers

10.1016/J.VACCINE.2010.03.074

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39882249&oldid=2092027200"